ClinicalTrials.gg

TargetBeta

FGFR3

fibroblast growth factor receptor 3 · also CEK2, JTK4, CD333, ACH · CD molecules

9 programs in company-led studies act on FGFR3, from 8 companies: 5 in phase 3, 1 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (9 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
nintedanibruleBoehringer Ingelheimphase 4761 runningFGFR1, FGFR2, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRBChEMBL
masitinibruleAB Sciencephase 3384 runningKIT, PDGFRA, PDGFRBChEMBL
futibatinibruleOtsukaphase 3104 runningFGFR1, FGFR2, FGFR4ChEMBL
infigratinibruleBridgeBiophase 3173 runningFGFR1, FGFR2, FGFR4ChEMBL
vepugratinibruleEli Lillyphase 353 running–NCIt
pemigatinibruleIncytephase 3161 runningFGFR1, FGFR2ChEMBL
dabogratinibruleTyra Biosciencesphase 255 running–NCIt
Anti-FGFR3 Antibody-drug Conjugate BHV-1530ruleBiohaven Therapeuticsphase 111 running–NCIt
FGFR3/4 Inhibitor TYRA-430ruleTyra Biosciencesphase 111 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.